Breaking a Vicious Cycle

Hayes, Daniel F.; Allen, Jeff; Compton, Carolyn C.; Gustavsen, Gary; Leonard, Debra G.B.; McCormack, Robert; Newcomer, Lee N.; Pothier, Kristin; Ransohoff, David F.; Schilsky, Richard L.; Sigal, Ellen V.; Taube, Sheila E.; Tunis, Sean

doi:10.1126/scitranslmed.3005950

Cited by 114 publications

(80 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 Based on these and many other successes, recent groups have recommended that all prospective clinical trials include formalized biospecimen banking for use in this context. 5 Cooperative groups that participate in clinical trials can use the prospectiveretrospective model to share both aspects of investigationsubject enrollment, treatment, and analysis-as well as post hoc investigations of new questions.…”

mentioning

confidence: 99%

Loss of antigenicity with tissue age in breast cancer

Combs

Han

Mani

et al. 2016

Laboratory Investigation

View full text Add to dashboard Cite

Archived tumor specimens, particularly those collected by large cooperative groups and trials, provide a wealth of material for post hoc clinical investigation. As these tissues are rigorously collected and preserved for many decades, subsequent use of the specimens to answer clinical questions must rely on the assumption that expression and detection of target biomarkers are not degraded with time. To test this assumption, we measured the expression of estrogen receptor (ER), human epidermal growth receptor 2 (HER2), and Ki67 in human breast carcinoma using quantitative immunofluorescence (QIF) in a series of formalin-fixed paraffin-embedded (FFPE) tissues from 1295 individual patients preserved for 7 to 53 years in four cohorts on tissue microarrays. Protein expression was measured using the automated quantitative analysis method for QIF. Change in quantitative protein expression over time was estimated in positive cases using both Pearson's correlation and a polynomial regression analysis with a random effects model. The average signal decreased with preservation time for all biomarkers measured. For ER and HER2, there was an average of 10% signal loss after 9.9 years and 8.5 years, respectively, compared with the most recent tissue. Detection of Ki67 expression was lost more rapidly, with 10% signal loss in just 4.5 years. Overall, these results demonstrate the need for adjustment of tissue age when studying FFPE biospecimens. The rate of antigenicity loss is biomarker specific and should be considered as an important variable for studies using archived tissues.

show abstract

mentioning

confidence: 99%

Loss of antigenicity with tissue age in breast cancer

Combs

Han

Mani

et al. 2016

Laboratory Investigation

View full text Add to dashboard Cite

show abstract

“…He continues by saying that people need to value biomarker tests as much as they value drugs and that researchers should have to do a biomarker study with the same amount of rigor as therapeutic trials [10]. This opinion was also expressed by Hayes et al in a recent article published in Science Translational Medicine [11].…”

mentioning

confidence: 90%

Companion diagnostics: the key to personalized medicine

Jørgensen¹

2015

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

“…Although there is still no absolute consensus regarding the representativity of the information obtained from circulating genetic material studies and there is an urgent need for techniques standardization, a considerable advance has been made [11]. Furthermore, following the identification of a potential novel biomarker, it has to undergo a validation process, consisting of three stages: the analytical validation, the clinical validation and the clinical utility [12] [13] [14] [15] [16]. Other aspect to be considered is the fact that CTCs do not constitute a homogeneous cell popula-tion even when coming from the same tumor.…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

Liquid Biopsy in Liquid Tumors

Ranuncolo¹

2017

JCT

View full text Add to dashboard Cite

The availability of a minimally invasive patient simple, capable of providing tumor information, represents a valuable clinical tool. The liquid biopsy has the potential to achieve this need. Circulating cell free DNA (ccfDNA), other circulating nucleic acids such as microRNA and circulating tumor cells (CTCs), can be obtained from a peripheral blood sample. Liquid biopsy has been particularly studied in solid tumors, specially of the epitelial origin, such as a pancreatic carcinoma and advanced breast cancer. It has been considerably less applied to the study of non-solid tumors. It represents an important source for diagnosis, prognosis and predictive information. Also it is suitable to evaluate response to therapy and drugs pharmacokinetics. It provides a unique opportunity to evaluate the disease evolution in serial blood samples collection, otherwise difficult to obtain. Liquid biopsy can be rehearsed using different circulating biological fluids such as whole blood, serum, plasma and lymph, as well as, non-circulating fluids such as urine, feces, saliva, bile and accumulated pathological fluids such as ascites. This review summarizes the current status of circulating material analysis in non-solid tunors. It is specially focused on Hodgkin Lymphoma and among Non-Hodgkin Lymphoma, it refers particularly to Diffuse Large B cell Lymphoma, the most common aggressive Non-Hodgkin Lymphoma derived from germinal center B-cells in adults. It further discusses the benefit of liquid biopsy in oncohemtaological diseases and potential clinical applications.

show abstract

Breaking a Vicious Cycle

Cited by 114 publications

References 29 publications

Loss of antigenicity with tissue age in breast cancer

Loss of antigenicity with tissue age in breast cancer

Companion diagnostics: the key to personalized medicine

Liquid Biopsy in Liquid Tumors

Contact Info

Product

Resources

About